Skip to main content
Kathryn Lurain, MD, Oncology, Bethesda, MD

KathrynLurainMDMPH

Oncology • Bethesda, MD

Hematologic Oncology

Assistant Research Physician

Join to view full profile

Dr. Lurain is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lurain's full profile

Already have an account?

  • Office

    HIV/AIDS Malignancy Branch National Cancer Institute
    10 Center Drive Room 6N110
    Bethesda, MD 20892
    Phone+1 301-250-5156

Summary

  • Dr. Kathryn Lurain is an oncologist in Bethesda, MD and is affiliated with National Institutes of Health Clinical Center. She received her medical degree from University of Virginia School of Medicine and has been in practice 5 years. She specializes in hematologic oncology.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2018
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 2012 - 2015
  • University of Virginia School of Medicine
    University of Virginia School of MedicineClass of 2012

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2012 - 2026
  • DC State Medical License
    DC State Medical License 2015 - 2016
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Discovery of Kaposi’s Sarcoma Herpesvirus-Encoded Circular RNAs and a Human Antiviral Circular RNA  
    Ramya Ramaswami, Kathryn Lurain, Thomas S Uldrick, Proceedings of the National Academy of Sciences

Lectures

  • Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • Checkpoint Immunotherapy Is Safe and Effective for HIV-Positive People with Cancer
    Checkpoint Immunotherapy Is Safe and Effective for HIV-Positive People with CancerJune 22nd, 2023

Professional Memberships

Dr. Kathryn Lurain, Dr. Kathryn Lurain, MD, Dr. K Lurain